

REMARKS

This preliminary amendment presents new claims 54-62, all of which are dependent claims. Submitted herewith is a check in the amount of \$162.00 to cover the fee set forth at 37 C.F.R. § 1.16(c) for filing eight additional claims in excess of twenty total claims.

Attached hereto (at page 4) is a sheet showing the claims introduced by this amendment. The attached sheet is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

It is submitted that no new matter is being introduced by the amendment as support for the new claims is found in the specification and claims as originally filed. Specifically, support for new claims 54-60 is found in the specification at, for example, page 10, lines 3-7, 16, 18-21, and 24; page 11, lines 11-20; and page 16, lines 10-27. Support for new claims 54-60 also is found in originally-filed claims 1, 13, and 15-18. Support for new claims 61 and 62 is found in the specification at page 12, lines 14-17 and 20-22, and in originally-filed claim 41. Accordingly, it is respectfully submitted that none of the newly-added claims 54-62 introduces any new matter and all are adequately supported pursuant to 35 U.S.C. § 112 by the application as originally filed.


An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

July 26, 2001

By


James J. Napoli
Reg. No. 32,361
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300 TELEPHONE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 54-62 have been added as follows:

54. (New) The method of claim 13 wherein the condition is selected from the group consisting of at least one of chronic pain, fibromyalgia and other somatoform disorders, and migraine headaches.

55. (New) The method of claim 54 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

56. (New) The method of claim 55 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

57. (New) The method of claim 56 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

58. (New) The method of claim 13 wherein the condition is chronic pain.

59. (New) The method of claim 13 wherein the condition is selected from the group consisting of at least one of fibromyalgia and other somatoform disorders.

60. (New) The method of claim 13 wherein the condition is a migraine headache.

61. (New) The method of claim 41 wherein the disorder is selected from the group consisting of at least one of chronic pain, fibromyalgia and other somatoform disorders, and migraine headaches.

62. (New) The method of claim 41 wherein the disorder is chronic pain.